(Press-News.org) Chapel Hill, N.C., April 17, 2015 - Achelios Therapeutics will announce results from a Phase IIa placebo-controlled clinical trial in moderate and severe migraine sufferers treated with TOPOFEN (TM), the company's proprietary topical anti-migraine therapy. The data to be presented demonstrate that the simple application of a well-known non-steroidal anti-inflammatory drug (NSAID), using the company's proprietary formulation on the skin, over the trigeminal nerve branches, can be a safe and effective alternative treatment for patients suffering from acute migraine.
William R. Bauer, M.D., Ph.D., FAAN, a neurologist and migraine headache specialist and advisor to Achelios, said, "Migraine remains a significant global cause of disability and disruption of activities of daily living. TOPOFEN results show promise to provide a safe and effective treatment that will positively impact the disabling effects of such a condition."
The results of the clinical trial will be presented at the Emerging Science session of the American Academy of Neurology annual meeting in Washington, D.C., on Wednesday, April 22. The study was conducted by scientists from Achelios and the Michigan Headache & Neurological Institute in Ann Arbor, Mich.
Wolfgang Liedtke, M.D., Ph.D., from Duke University will present the results as a member of the team that conducted the research and a paid advisor to Achelios. Liedtke, an associate professor of neurology and attending physician in the Duke Pain Medicine clinics, said, "The results of the study are encouraging, and those of us who treat migraine think it may lead to a meaningful alternative treatment for a substantial number of migraineurs. This study showed that it may be possible to affect severe migraine, which can be a debilitating neurological pain condition, with a topical application to facial trigeminal nerve endings, which was unexpected."
Crist Frangakis, Ph.D., president and CEO of Achelios Therapeutics, the study sponsor, said, "The positive results of this study provide preliminary evidence that migraines can be effectively treated topically without the safety and side effects challenges that often accompany systemic oral medications. Serious side effects of NSAIDs, such as stomach bleeding and ulcers, result in more than 100,000 hospitalizations and thousands of deaths each year in the U.S. With TOPOFEN physicians and patients, especially those with cardiovascular risks, will have a new treatment option."
The randomized, crossover, double-blind, placebo-controlled study involved 48 screened adults with a history of episodic migraine with and without aura (the warning signs that can precede headache pain in about 20 percent of sufferers). Patients were instructed to treat five moderate to severe migraines by applying the TOPOFEN gel on the skin, over the three branches of the trigeminal nerve, and to record their symptoms on an electronic diary.
Compared with placebo, TOPOFEN resulted in greater improvement in pain assessments after study drug application, a faster time to pain response, a reduction of migraine-associated symptoms such as nausea, light and sound hypersensitivity, and greater suppression of pain over the 24-hour period that patients were asked to follow each migraine once they applied the gel.
Of the severe migraine patients, 77 percent experienced relief of pain and migraine-associated symptoms and 45 percent had sustained pain relief from two to 24 hours compared to 15 percent of placebo. Also 50 percent of patients who treated their severe pain with TOPOFEN were pain free at 24 hours compared to 25 percent of placebo-treated patients. Patients whose severe headaches were treated with TOPOFEN were at least three times as likely to experience complete relief of associated symptoms (nausea and photophobia) versus placebo. Some patients experienced application-site irritation, predominantly mild or moderate. That was the only reported side effect, which resolved quickly.
INFORMATION:
About TOPOFEN (TM)
TOPOFEN, also known as ELS-M11, is a proprietary gel formulation consisting of 5 percent ketoprofen, a potent NSAID. The gel formulation was developed to permeate human skin rapidly and efficiently. Indications that TOPOFEN is currently being evaluated for include acute and chronic migraine, peripheral joint pain, sprains and strains, temporomandibular joint disease, and post-surgical inflammatory pain.
NSAIDs are a widely used class of drugs that relieve pain, reduce fever and stem inflammation. They include aspirin, ibuprofen, naproxen and others. Topical NSAIDs represent an alternative to the oral form of the drugs, which have known safety issues and side effects such as gastrointestinal irritation, bleeding and ulcers, especially when used in higher doses that are often required to relieve migraine pain.
About Acute Migraine
At least 37 million Americans suffer from migraine, according to the National Headache Foundation. The prevalence of migraine peaks at about 40 years of age and commonly occurs during the peak productive years of 25 to 55. The socio-economic cost burden is estimated to exceed $25 billion annually.
The trigeminal nerve is a major pain pathway that supplies all sensory innervation for the head, face and all adjacent sentient structures such as the teeth, eyeball, sinuses, and, importantly for headaches such as migraine, the dura mater that surrounds the brain, which sticks to the bone of the skull like an internal wallpaper. All of these structures can activate pain-sensing trigeminal nerve endings.
Migraine is believed to occur when brain cells trigger the trigeminal nerve to release neuropeptides that enhance inflammation and make the sensitive dura mater hypersensitive. These events cause sharp pain because blood vessels also dilate, affecting the highly sensitized dura and making the pain pulse-synchronous. Migraine headaches are typically on one side of the head and are felt around the eye or temple.
About Achelios Therapeutics
Achelios Therapeutics, established in 2012 in Chapel Hill, N.C., is a privately held pharmaceutical-development company focused on developing topical drugs for the treatment of migraine and peripheral pain. It is backed by private capital financing, and its research has been supported in part by a Small Business Research Loan from the N.C. Biotechnology Center. The company's name is derived from the mythological Greek moon goddess "Achelois," which loosely translates as "she who washes away pain." (Editors: Note the slightly different spelling of the company name, Achelios, and the Greek moon goddess, Achelois.)
Contact: For media inquiries or potential partnering opportunities, contact Crist Frangakis, Ph.D., president and CEO, Achelios Therapeutics, at 919-354-6233 (office); email: cfrangakis@achelios.com.
Study shows there are six different types of obese people
Treating individuals according to which 'type' could be more effective
Targeted strategies would also mean a more efficient use of NHS services
One size does not fit all when it comes to tackling obesity, according to a new study by the University of Sheffield.
Researchers looking at how to tackle the country's obesity issue - which costs the NHS £6billion pounds every year* - found that currently individuals are often treated the same regardless of how healthy they are, where they live or their ...
A new paper by a team of researchers led by Karel Matous, College of Engineering Associate Professor of Computational Mechanics in the Department of Aerospace and Mechanical Engineering at the University of Notre Dame, describes how an accurate statistical description of heterogeneous particulate materials, which is used within statistical micromechanics theories, governs the overall thermo-mechanical properties. This detailed statistical description was computed using a novel adaptive interpolation/integration scheme on the nation's largest parallel supercomputers. Quantifying ...
According to the World Health Organization's 2014 World Malaria Report, there are an estimated 198 million cases of malaria worldwide with 3.3 billion people at risk for contracting the infection. Although the impact of malaria is still significant, the statistics reflect a considerable reduction in the global malaria burden. Since 2010, disease transmission has been reduced by 30 percent and mortality due to malaria has decreased by almost half.
Artemisinins are powerful drugs that have the most rapid action of all current drugs against Plasmodium falciparum, the parasite ...
For decades, frustrated parents and teachers have barked at fidgety children with ADHD to "Sit still and concentrate!"
But new research shows that if you want ADHD kids to learn, you have to let them squirm. The foot-tapping, leg-swinging and chair-scooting movements of children with attention-deficit/hyperactivity disorder are actually vital to how they remember information and work out complex cognitive tasks, according to a study published in an early online release of the Journal of Abnormal Child Psychology.
The findings show the longtime prevailing methods for ...
April 17, 2015 - A multicenter team of U.S. and Venezuelan scientists, led by researchers from NYU Langone Medical Center, have discovered the most diverse collection of bodily bacteria yet in humans among an isolated tribe of Yanomami Indians in the remote Amazonian jungles of southern Venezuela.
By comparison, the microbiome of people living in industrialized countries is about 40 percent less diverse, the scientists estimate. The team reports its findings today in the journal Science Advances.
The results, the researchers say, suggest a link between modern antibiotics ...
Research by scientists at The University of Manchester has revealed that the colour of light has a major impact on how the brain clock measures time of day and on how the animals' physiology and behavior adjust accordingly. The study, for the first time, provides a neuronal mechanism for how our internal clock can measure changes in light colour that accompany dawn and dusk.
In research publishing on April 17th in the Open Access journal PLOS Biology, the researchers looked at the change in light around dawn and dusk to analyze whether colour could be used to determine ...
Scientists from the Icahn School of Medicine, collaborating with a multicenter team of U.S. and Venezuelan researchers, have discovered the most diverse collection of bacteria yet in humans among an isolated tribe of Yanomami Amerindians in the remote Amazonian jungles of Venezuela. Bacterial diversity in the Yanomami, previously unexposed to antibiotics or industrialized diets, was found to be nearly double that of people living in industrialized countries, and was also significantly higher than in other remote populations moderately exposed to modern practices. The team ...
An annual report from Tel Aviv University researchers reveals that anti-Semitic incidents rose dramatically worldwide in 2014, with violent attacks on Jews ranging from armed assaults to vandalism against synagogues, schools, and cemeteries.
The report, released on April 15 by TAU's Kantor Center for the Study of Contemporary European Jewry, recorded 766 incidents, mostly in Western Europe, compared to 554 in 2013 -- a surge of nearly 40 percent. The report called 2014 the worst year for anti-Semitic attacks since 2009. The authors of the report characterized such attacks ...
Researchers at the University of California, San Diego School of Medicine have created an in vitro, live-cell artificial vessel that can be used to study both the application and effects of devices used to extract life-threatening blood clots in the brain. The artificial vessel could have significant implications for future development of endovascular technologies, including reducing the need for animal models to test new devices or approaches.
The findings are published in the current online issue of the journal Stroke.
Cerebrovascular disease covers a group of dysfunctions ...
Early indicators of the malaria parasite in Africa developing resistance to the most effective drug available have been confirmed, according to new research published in Antimicrobial Agents and Chemotherapy.
Researchers at the London School of Hygiene & Tropical Medicine found Plasmodium falciparum malaria parasites with a mutation to the gene Ap2mu were less sensitive to the antimalarial drug artemisinin.
A study in 2013, also led by the School, suggested an initial link between a mutation in the ap2mu gene and low levels of malaria parasites remaining in the blood ...
